Skip to content

Using GLP-1s

Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses

On a U-100 insulin syringe, "units" measure volume: 100 units make 1 mL. Your vial's concentration is what turns a prescribed mg dose into a unit count. This walkthrough teaches the arithmetic with worked examples at different concentrations, explains the dosing errors the FDA has documented, and gives a checklist to go through with your pharmacist. It teaches you to read the syringe. It does not prescribe doses.

By the glp1.how editorial teamReviewed 5 min read

Evidence-backed

A patient is told to draw "5 units" of compounded semaglutide from a vial. They pick up the 1 mL insulin syringe the pharmacy sent, find a "5" printed near the halfway mark, and draw 50 units. That is ten times the intended dose. The FDA describes this exact scenario in its adverse event reports, and it happens because insulin syringes use a unit system most people have never had to read. This article teaches you how to read one. It does not tell you what dose to take. That number comes from your prescriber, and you should confirm the math below with your dispensing pharmacist before you inject anything.

The one fact that unlocks the syringe

Standard insulin syringes are "U-100" syringes. The scale printed on the barrel divides 1 milliliter (mL) into 100 "units":

  • 100 units = 1 mL
  • 1 unit = 0.01 mL

On the syringe itself, a "unit" measures volume, not medication. Ten units is 0.1 mL of liquid. How much drug is in those 10 units depends on the concentration of the liquid you're drawing from.

Your prescription is written in milligrams (mg). Your syringe reads in units of volume. The number that connects them is the concentration printed on your vial's label, in mg per mL. The conversion is one line of arithmetic:

units = (dose in mg ÷ concentration in mg/mL) × 100

Divide the dose by the concentration to get milliliters, then multiply by 100, because each mL is 100 units.

Why the same dose can be a different number of units

This is the main way compounded vial-and-syringe dosing goes wrong. Compounding pharmacies use different concentrations, so a unit count copied from someone else, or from your own previous vial, can be flatly wrong. Here is the same prescribed dose at two concentrations.

Example 1: 0.25 mg dose, vial labeled 2.5 mg/mL. 0.25 ÷ 2.5 = 0.1 mL. Then 0.1 × 100 = 10 units.

Example 2: the same 0.25 mg dose, vial labeled 5 mg/mL. 0.25 ÷ 5 = 0.05 mL. Then 0.05 × 100 = 5 units.

Same prescription, half the units, because the second vial is twice as concentrated. If you drew 10 units from that second vial, you'd take double your dose.

Example 3: 1 mg dose, vial labeled 2.5 mg/mL. 1 ÷ 2.5 = 0.4 mL. Then 0.4 × 100 = 40 units.

So "how many units do I draw?" has no universal answer, and forum posts and screenshots with specific unit counts are dangerous to copy. Our guide on GLP-1 microdosing makes the same warning at length. The only concentration that matters is the one on your current vial's label, and it can change between refills.

Syringe sizes and their markings

U-100 insulin syringes come in three common barrel sizes, and the markings differ:

  • 0.3 mL holds 30 units. It's usually marked in 1-unit steps, and some models add half-unit marks. It's the easiest to read for small doses.
  • 0.5 mL holds 50 units, usually marked in 1-unit steps.
  • 1.0 mL holds 100 units and is often marked only in 2-unit steps, with numbers at 10, 20, 30 and so on.

Before you read any barrel, check that the syringe really is a U-100 syringe. Syringes marked for other concentrations exist. U-40 syringes, for example, are common for veterinary insulin, and one case report describes a patient who drew his U-100 insulin with U-40 syringes and had repeated low blood sugar episodes (Barrera and Murvelashvili, Case Reports in Endocrinology, 2019, DOI (external link)). On those syringes the unit lines stand for a different volume, and the arithmetic above doesn't apply. On a 0.3 mL syringe with half-unit markings, count carefully: the short lines between whole units are half-units.

Small doses on a big syringe are where misreads happen. On a 1 mL barrel, a 5-unit dose sits just above the needle, while the printed "50" sits mid-barrel and looks like a reasonable target. The FDA recommends that providers supply a syringe size that fits the intended dose. If your dose is 5 units, ask whether a 0.3 mL syringe makes sense.

What the FDA has documented

In a July 2024 alert, the FDA reported adverse events, some requiring hospitalization, from dosing errors with compounded injectable semaglutide. Most reports described patients drawing more than the prescribed dose from a multiple-dose vial and taking five to 20 times the intended dose. Confusion between milliliters, milligrams, and "units" contributed. The 5-units-versus-50-units mistake above is the FDA's own example. Providers made errors too: several reports describe clinicians miscalculating mg-to-unit conversions, producing five to 10 times the intended dose. Reported adverse events included nausea, vomiting, abdominal pain, fainting, headache, dehydration, acute pancreatitis, and gallstones. A separate poison-control case series in the Journal of the American Pharmacists Association found the same pattern, including 10-fold self-administration errors (Lambson et al., 2023, DOI (external link)).

Compounded GLP-1 vials are also less common than they were when that alert came out. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025, which ended the period when compounders could make copies of these drugs at scale. See the compounding debate for what that means for access as of September 2026. If you do have a compounded vial, the arithmetic here still applies.

Checklist for your pharmacist

Before your first injection from any new vial, including refills, confirm with the dispensing pharmacist:

  1. The concentration on this vial's label, in mg/mL, read aloud from the vial in your hand.
  2. Your prescribed dose in mg, and the resulting unit count and mL volume. Ask the pharmacist to state it; don't just offer your own answer for approval.
  3. That your syringe size fits the dose, and which line you'll fill to, ideally shown to you.
  4. Whether the concentration changed since your last fill, and the new unit count if it did.
  5. What to do if you draw the wrong amount: who to call, and which symptoms need medical attention.

Reading a U-100 syringe comes down to one fact (100 units = 1 mL) and one line of division. The risk comes from assuming a unit count instead of working it out from your own vial's labeled concentration at every fill.

Study findings above are attributed to their authors and were located via PubMed.

This article is arithmetic education, not medical advice, and it does not prescribe or endorse any dose. Your dose comes from your prescriber; your unit count should be confirmed by your dispensing pharmacist.

compoundingdosingsyringessafetydosing-errorsunits

Common questions

Questions people often ask about this topic.

  • How many units do I draw for my compounded GLP-1 dose?

    There's no universal answer. The unit count depends on the concentration printed on your vial's label, which varies between compounding pharmacies and can change between refills. The conversion is: units = (dose in mg ÷ concentration in mg/mL) × 100. The same 0.25 mg dose is 10 units from a 2.5 mg/mL vial but only 5 units from a 5 mg/mL vial, so copying a unit count from a forum post, or even from your own previous vial, can be flatly wrong. Always confirm the number with your dispensing pharmacist before injecting.

  • What does a "unit" on an insulin syringe actually mean?

    On a standard U-100 insulin syringe, a unit measures volume, not medication: 100 units = 1 mL, so 1 unit = 0.01 mL. How much drug is in those units depends on the concentration of the liquid you're drawing from. That's why the vial's labeled concentration in mg/mL is what links your prescribed mg dose to the unit count you draw.

  • How do dosing errors with compounded semaglutide actually happen?

    The FDA reported adverse events, some requiring hospitalization, in which patients drew five to 20 times the intended dose from multiple-dose vials, with confusion between milliliters, milligrams, and units as a contributing factor. In the FDA's own example, a patient told to draw 5 units sees the printed "5" near the middle of a 1 mL syringe and draws 50 units, ten times the dose. Providers made errors too, with several reports of clinicians miscalculating mg-to-unit conversions.

  • Does syringe size matter for small doses?

    Yes. Small doses on a big syringe are where misreads happen. On a 1 mL barrel (100 units, often marked only in 2-unit steps), a 5-unit dose sits just above the needle while the printed "50" sits mid-barrel and looks like a reasonable target. The FDA recommends that providers supply a syringe size that fits the dose. If yours is small, ask whether a 0.3 mL syringe makes sense.

  • What should I confirm with my pharmacist before injecting from a new vial?

    Before the first injection from any new vial, including refills, confirm: the concentration on the label, read aloud from the vial in your hand; your prescribed dose in mg and the unit count the pharmacist states (not just your own answer approved); that your syringe size fits the dose and which line to fill to; whether the concentration changed since your last fill; and what to do if you draw the wrong amount.

Evidence

The sources behind this article, labeled by type and strength.

Supporting5

Revision history

Updated 3 times since Sep 2, 2026 · show changes
  1. v4

    Evidence sources 2 → 5

  2. v3

    Common questions revised

  3. v2

    Summary rewritten; Body revised

  4. v1

    Change tracking began

Related guides

  • Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens · Brand-name GLP-1 pens measure the dose for you. Compounded versions usually come as a vial and syringes, so you measure it yourself. Why that raises the stakes on accuracy, what to ask your pharmacy, and where compounding stands after the shortages ended.
  • Safe sharps disposal for GLP-1 injectors · Every GLP-1 injection ends with a needle you have to put somewhere. This guide walks through the FDA's two-step system: a proper sharps container (or an acceptable heavy-duty household stand-in), the short list of things never to do with a used needle, how to find your community's disposal rules, and what changes when you travel.
  • GLP-1 microdosing: what it means, why people do it, and what the evidence actually says · "Microdosing" GLP-1s is all over social media: using much smaller doses than the label calls for, for weight maintenance, side-effect avoidance, cost, or vague wellness claims. What the term means, the real medicine it borrows from, why no clinical trial has tested it, the specific risks of the DIY version, and how to have a lower-dose conversation with your prescriber instead.
  • What happens if you accidentally take a double dose · Injecting twice, or using the wrong-strength pen, does happen. What to expect in the days after, when to call your prescriber or Poison Help, and how to keep it from happening again.
  • Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration · Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
  • Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found · If you've lost weight on Zepbound or Wegovy and want off the weekly injection, can a daily pill hold your results? One randomized trial has now tested exactly that, and Wegovy users also have an on-label switch to Wegovy tablets. This guide covers what the trial found, how much weight people kept, what the switch felt like, and the big question the trial didn't answer.

Related terms

  • Compounded semaglutide · A version of semaglutide made by a compounding pharmacy rather than the original manufacturer — not FDA-approved as a standalone product.
  • U-100 insulin syringe (units) · A syringe marked in "units" where 100 units equal 1 mL — designed for U-100 insulin but commonly used to draw compounded GLP-1 doses from vials.
  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • Pancreatitis · Inflammation of the pancreas — a rare but serious potential side effect of GLP-1 medications requiring immediate medical attention.
  • Tirzepatide · A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.

Was this helpful?

Improve this page